ReviewBMC medicine2014
Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis?
Review in BMC medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Meta-Analysis: Diagnostic Accuracy of Anti-Carbamylated Protein Antibody for Rheumatoid Arthritis.PloS one · 2016Pooled it
- Rheumatoid Arthritis Diagnostic and Monitoring Testing Patterns by Physicians and Advanced Practice Providers in the United States, 2012 to 2024.ACR open rheumatology · 2026Article
- Rheumatoid Arthritis: Biomarkers and the Latest Breakthroughs.International journal of molecular sciences · 2025Review
- Association of circulating levels of anti-CarP antibodies with disease activity, disability and radiological damage in rheumatoid arthritis patients: an open-label, observational study.Scientific reports · 2025Observational
- Article
- Targeting the serum marker interleukin 9 improves the underlying characterization and immune homeostasis in rheumatoid arthritis.Central-European journal of immunology · 2024Article
- Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.Frontiers in immunology · 2023Article
- Computer-Assisted Image Analysis in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis.ACR open rheumatology · 2022Article
- Plasma MicroRNAs (miR-146a, miR-103a, and miR-155) as Potential Biomarkers for Rheumatoid Arthritis (RA) and Disease Activity in Iranian Patients.Mediterranean journal of rheumatology · 2021Article
- Management of Rheumatoid Arthritis: An Overview.Cells · 2021Review
- [Significance of anti-carbamylated protein antibodies in patients with rheumatoid arthritis-associated intersitial lung disease].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019Article
- Vitamin K homologs as potential biomarkers for disease activity in patients with rheumatoid arthritis.Journal of bone and mineral metabolism · 2017Article
- Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor.Saudi medical journal · 2017Article
- Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients.The Malaysian journal of medical sciences : MJMS · 2016Article
- Advances and challenges in hemophilic arthropathy.Seminars in hematology · 2016Review
- Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting.BMC medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a common autoimmune disease in which a heterogeneous course and different pathogenic mechanisms are implicated in chronic inflammation and joint destruction. Despite the diagnostic contribution of anti-citrullinated protein/peptide antibodies (ACPAs) and rheumatoid factors, about one-third of RA patients remain seronegative. ACPAs belong to a heterogeneous family of autoantibodies targeting citrullinated proteins, including myelin-basic protein, several histone proteins, filaggrin and fibrin, fibrinogen or vimentin. In addition to ACPAs, antibodies directed against other post-translationally modified-carbamylated proteins (anti-CarP) were detected in up to 30% of ACPA-negative patients. Using phage display technology, further autoantibodies were recently discovered as candidate biomarkers for seronegative RA patients. Furthermore, in clinical practice, ultrasound may reveal subclinical synovitis and radiographically undetected bone erosions. To improve diagnostic certainty in undifferentiated arthritis and seronegative patients, ultrasound imaging and several new biomarkers may help to identify at risk patients and those with early disease. In this commentary we summarize recent advances in joint ultrasound and future potential of serological biomarkers to improve diagnosis of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.